Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.

AU Wells, KR Flaherty, KK Brown, Y Inoue, A Devaraj, L Richeldi, T Moua, B Crestani, WA Wuyts, S Stowasser, M Quaresma, RG Goeldner, INBUILD trial investigators

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science